Vaxcyte, INC Form 4 insider transactions

Vaxcyte, Inc. Director Jacks Lee was granted 3,041 restricted stock units and options to purchase 15,372 shares of common stock on June 12, 2025.

Vaxcyte, Inc. Director Anne S. Drapeau has reported the acquisition of 3,041 shares of common stock through restricted stock units and 15,372 stock options, increasing her beneficial ownership in the company.

Vaxcyte, Inc. Director Carlos V. Paya was granted 3,041 restricted stock units and 15,372 stock options as part of his compensation, aligning his interests with shareholders.

Director Olivier Brandicourt acquired stock options in Vaxcyte, Inc. on May 1, 2025.

Director Heath Lukatch exercised stock options at Vaxcyte, Inc. on April 8, 2025, resulting in changes to his beneficial ownership of company stock.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., reports exercising stock options and subsequent beneficial ownership of securities.

Vaxcyte's CEO, Grant Pickering, executed stock options at prices of $5.35 and $20.93, altering his beneficial ownership in the company.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, CFO of Vaxcyte, Inc., reports acquisition and disposal of common stock and stock options.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., reports the acquisition and disposal of common stock and stock options.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports acquisition and disposal of common stock and stock options.

Vaxcyte's Chief Operating Officer, Jim Wassil, reports multiple transactions involving the company's common stock and stock options.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported a transfer of 74,000 common stock shares to a charitable remainder trust on December 31, 2024.

Grant Pickering, CEO of Vaxcyte, reports acquisition of shares through restricted stock units and disposition of shares to cover tax obligations.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares on January 21, 2025, under a pre-arranged 10b5-1 trading plan.

Vaxcyte director Teri Loxam sold a total of 7,250 shares of common stock on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, executed stock sales and exercised stock options on January 2, 2025, according to a recent SEC filing.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold shares on December 16, 2024.

Director Carlos V. Paya of Vaxcyte, Inc. reports the transfer of shares to a family trust and the grant of stock options.

Vaxcyte CEO Grant Pickering sold a total of 2,366 shares of common stock on December 9, 2024, through a pre-arranged 10b5-1 trading plan.

Vaxcyte's SVP, General Counsel & Corporate Secretary, Mikhail Eydelman, reported multiple transactions involving the company's stock, including a gift, option exercise, and sales under a pre-arranged trading plan.

Vaxcyte CEO Grant Pickering sold a total of 15,000 shares of common stock in multiple transactions on December 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Vaxcyte CEO Grant Pickering reported a gift of 710 common shares and details of beneficial ownership including shares held in trust for his children.